<DOC>
	<DOCNO>NCT01217736</DOCNO>
	<brief_summary>The objective study determine magnitude effect direct renin inhibition VTP-27999 renal plasma flow kidney function .</brief_summary>
	<brief_title>Direct Renin Inhibition Kidney</brief_title>
	<detailed_description />
	<criteria>Healthy adult male female , 1875 year age Female subject must postmenopausal surgically sterilize . Postmenopausal females must regular menstrual bleeding least one ( 1 ) year prior initial dosing . Menopause confirm plasma serum FSH level screen 23.0116.3 mIU/ml . Female subject report surgical sterilization must procedure least six ( 6 ) month prior initial dosing . Male subject , able father child , must willing use approve birth control method 2 week follow completion study . Subjects 18 subject 75 year Diabetes Mellitus and/or kidney disease Myocardial infarction , stroke , cardiovascular revascularization/angioplasty within last 6 month Unstable angina pectoris CAD require treatment exclude concomitant medication History of/or symptom consistent congestive heart failure Hypertension History leave ventricular ejection fraction &lt; 45 % Current smoker nicotine patch Pregnant lactating female Cancer life threaten illness expect death within 2 year completion study Serum creatinine &gt; 1.4 mg/dl Serum potassium &lt; 3.5 &gt; 5.2 mmol/L without medication Serum albumin &lt; 2.0 g/dL Hemoglobin &lt; 11.5 g/dL Hematocrit &lt; 34 % Any serum AST &gt; /= 60 ALT &gt; /= 75 IU/L Use prescription drug may affect reninangiotensinaldosterone system know effect renal hemodynamics allow within 10 day prior dose study Use CYP3A4 inhibitor ( e.g . Diltiazem , Ketoconazole , Nifedipine , Verapamil ) Use prescription medication prohibit within 14 day ( , know , least 5 halflives , long ) prior dose , unless approve Investigator Sponsor Use overthecounter ( OTC ) medication , include herbal product , prohibit within 14 day prior dose , unless approve Investigator Sponsor Donation loss 400 mL blood within 8 week prior first dose A known hypersensitivity contraindication study drug ( Aliskiren ) drug similar study drug PAH , inulin Any surgical medical condition alters absorption , distribution , metabolism excretion drug may jeopardize patient subject study , include gastric bypass History drug alcohol abuse within 12 month prior dose , evidence abuse indicate past medical history Acute infection and/or significant illness within 3 week plan enrollment study Any medical condition investigator 's opinion , render subject unable complete study would produce significant risk subject Administration investigational drug within 30 day plan dose study Poor intravenous ( IV ) access determine study staff</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>